Home › Atherosclerosis › Texas › El Paso
Atherosclerosis clinical trials in El Paso, TX
4 studies for Atherosclerosis are looking for participants at sites in and around El Paso (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
RecruitingPhase 3
- David Turbay, MD, El Paso
- Academy of Diabetes Thyroid and Endocrine, El Paso
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
RecruitingPhase 2/3
- Davita Clinical Research, El Paso
- DaVita Clinical Research - Horizon, El Paso
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
RecruitingPhase 3
- Research Site, El Paso
Pelacarsen Roll-over Extension Program
RecruitingPhase 3
- David Turbay MD PLLC, El Paso
About Atherosclerosis
Atherosclerosis is hardening and narrowing of the arteries caused by the buildup of a fatty substance called plaque. Learn about the risks and prevention.
More about Atherosclerosis on MedlinePlus
Atherosclerosis trials in other cities
- Boston, MA10 studies
- Houston, TX10 studies
- Washington, DC9 studies
- Arlington, VA8 studies
- Orlando, FL8 studies
- Hialeah, FL8 studies
- Durham, NC7 studies
- Memphis, TN7 studies
- Miami, FL7 studies
- Dallas, TX7 studies
- Las Vegas, NV7 studies
- Minneapolis, MN6 studies
Other studies in El Paso
- Obesity10 studies
- Overweight8 studies
- Heart Failure7 studies
- Non-Small Cell Lung Cancer6 studies
- Breast Cancer6 studies
- COPD5 studies
- Metastatic Cancer5 studies
- Burkitt Lymphoma4 studies
- Lung Cancer4 studies
- Asthma4 studies
- Cancer (all types)4 studies
- Idiopathic Pulmonary Fibrosis4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.